JPH06336426A - Metabolic regulator - Google Patents
Metabolic regulatorInfo
- Publication number
- JPH06336426A JPH06336426A JP12725793A JP12725793A JPH06336426A JP H06336426 A JPH06336426 A JP H06336426A JP 12725793 A JP12725793 A JP 12725793A JP 12725793 A JP12725793 A JP 12725793A JP H06336426 A JPH06336426 A JP H06336426A
- Authority
- JP
- Japan
- Prior art keywords
- valine
- proline
- leucine
- alanine
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】この発明は、スズメバチ（Vespa
属）の幼虫が分泌するだ液中に含まれるアミノ酸類で構
成される組成物の知見から得られた脂肪酸、糖の代謝調
節剤に関する。BACKGROUND OF THE INVENTION The present invention is directed to hornets (Vespa).
The present invention relates to a fatty acid and sugar metabolism regulator obtained from the knowledge of a composition composed of amino acids contained in saliva secreted by larvae of the genus).
【０００２】[0002]
【従来の技術及び発明の解決しようとする課題】従来、
スズメバチの幼虫に関する報告、特に幼虫が分泌するだ
液に関する報告はほとんどなく、その組成は全く解明さ
さていなかった。またスズメバチの驚異的な筋持続力は
どの様な栄養に由来するのかも全く不明であった。本発
明者らは、種々のスズメバチの幼虫が分泌するだ液につ
いて研究し、その組成を明らかにするとともに、その組
成物が極めて有効な脂質、糖質代謝調節作用を有するこ
とを見出し、その有効成分を解明してきた。スズメバチ
の幼虫が分泌するアミノ酸栄養液は、経口投与により運
動時の脂質および糖質代謝を調節することが明らかにな
っている（例えば、特願平１−１５０７８８号公報、特
願平２−２１０８９５号公報、特願平２−２３２９７７
号公報、特願平２−２４０９６１号公報参照）。本発明
者は、種々のスズメバチの幼虫が分泌するだ液について
さらに研究し、その組成を明らかにするとともに、その
組成物が極めて有効な脂肪酸、糖、乳酸代謝調節作用を
有することを見出し、その有効成分を解明して来た。本
発明は、血中脂肪酸及び血糖値の調節作用を有する代謝
調節剤を提供することを目的とする。2. Description of the Related Art Conventionally, the problems to be solved by the invention are as follows.
There have been few reports on hornet larvae, especially saliva secreted by larvae, and their composition has not been clarified at all. Moreover, it was completely unknown what kind of nutrition originated the muscular endurance of the wasp. The present inventors have studied the saliva secreted by various hornet larvae, clarified its composition, found that the composition has an extremely effective lipid and carbohydrate metabolism regulating effect, and The ingredients have been clarified. It has been clarified that the amino acid nutrient solution secreted by hornet larvae regulates lipid and sugar metabolism during exercise by oral administration (for example, Japanese Patent Application Nos. 1-150788 and 2-210895). Publication, Japanese Patent Application No. 2-232977
(See Japanese Patent Application No. 2-240961). The present inventor further studied the saliva secreted by various hornet larvae, clarified its composition, and found that the composition had extremely effective fatty acid, sugar, and lactic acid metabolism regulating actions, and The active ingredients have been clarified. An object of the present invention is to provide a metabolic regulator having an action of regulating blood fatty acid and blood glucose level.
【０００３】[0003]
【課題を解決するための手段】本発明者は、種々のスズ
メバチの幼虫が分泌するだ液に含まれる組成物の組成に
ついて鋭意研究を続けた結果、下記のアミノ酸組成物が
極めて有効な脂肪酸、糖代謝調節作用を有することを見
出し、本発明を完成するに至った。すなわち本発明は、
(1) イソロイシン、ロイシン、リジン、バリン、セリ
ン、プロリン、グリシン、アラニン、およびスレオニン
を主成分とする脂肪酸、糖代謝調節剤；(2) イソロイシ
ン、ロイシン、バリン、セリン、プロリン、グリシン、
アラニン、およびスレオニンを主成分とする脂肪酸、糖
代謝調節剤；(3) イソロイシン、ロイシン、リジン、バ
リン、プロリン、グリシン、およびアラニンを主成分と
する脂肪酸、糖代謝調節剤；ならびに(4) イソロイシ
ン、ロイシン、リジン、バリン、プロリン、およびアラ
ニンを主成分とする脂肪酸、糖代謝調節剤を提供するも
のである。Means for Solving the Problems As a result of continuing diligent research on the composition of the composition contained in the saliva secreted by various hornet larvae, the present inventors have found that the following amino acid composition is a very effective fatty acid, They found that they have a sugar metabolism regulating action, and completed the present invention. That is, the present invention is
(1) Isoleucine, leucine, lysine, valine, serine, proline, glycine, alanine, and a fatty acid mainly composed of threonine, a sugar metabolism regulator; (2) isoleucine, leucine, valine, serine, proline, glycine,
Alanine and threonine-based fatty acids and sugar metabolism regulators; (3) Isoleucine, leucine, lysine, valine, proline, glycine, and alanine-based fatty acids and sugar metabolism regulators; and (4) Isoleucine The present invention provides a fatty acid and sugar metabolism regulator containing, as a main component, leucine, lysine, valine, proline, and alanine.
【０００４】本発明のイソロイシン、ロイシン、リジ
ン、バリン、セリン、プロリン、グリシン、アラニン、
およびスレオニンを主成分とする脂肪酸、糖代謝調節剤
は、好ましくは、イソロイシン（Ile)を0.５〜0.８モ
ル、ロイシン（Leu)を0.７〜1.１モル、リジン（Lys)を
1.４〜1.８モル、バリン（Val)を0.６〜1.１モル、セリ
ン(Ser) を0.２〜0.５モル、プロリン（Pro)を2.５〜2.
９モル、グリシン（Gly)を2.６〜3.１モル、アラニン(A
la) を0.７〜1.１モル、およびスレオニン（Thr)を0.８
〜1.２モルの割合で含有することができる。Isoleucine, leucine, lysine, valine, serine, proline, glycine, alanine of the present invention,
And, the fatty acid mainly composed of threonine and the sugar metabolism regulator are preferably 0.5 to 0.8 mol of isoleucine (Ile), 0.7 to 1.1 mol of leucine (Leu), and lysine (Lys). To
1.4-1.8 mol, valine (Val) 0.6-1.1 mol, serine (Ser) 0.2-0.5 mol, proline (Pro) 2.5-2.
9 mol, 2.6-3.1 mol of glycine (Gly), alanine (A
la) to 0.7 to 1.1 mol, and threonine (Thr) to 0.8
It can be contained at a ratio of up to 1.2 mol.
【０００５】本発明のイソロイシン、ロイシン、バリ
ン、セリン、プロリン、グリシン、アラニン、およびス
レオニンを主成分とする脂肪酸、糖代謝調節剤は、好ま
しくは、イソロイシンを1.２〜1.５モル、ロイシンを1.
６〜2.１モル、バリンを1.５〜2.０モル、セリンを0.５
〜0.９モル、プロリンを5.２〜5.６モル、グリシンを5.
５〜6.０モル、アラニンを1.６〜2.０モル、およびスレ
オニンを2.０〜2.４モルの割合で含有することができ
る。また、本発明のイソロイシン、ロイシン、リジン、
バリン、プロリン、グリシン、およびアラニンを主成分
とする脂肪酸、糖代謝調節剤は、好ましくは、イソロイ
シンを1.２〜1.６モル、ロイシンを1.６〜2.２モル、リ
ジンを3.０〜3.５モル、バリンを1.５〜2.０モル、プロ
リンを5.２〜5.６モル、グリシンを5.５〜6.０モル、お
よびアラニンを1.６〜2.０モルの割合で含有することが
できる。さらに、本発明のイソロイシン、ロイシン、リ
ジン、バリン、プロリン、およびアラニンを主成分とす
る脂肪酸、糖代謝調節剤は、好ましくは、イソロイシン
を1.２〜1.５モル、ロイシンを1.６〜2.１モル、リジン
を3.０〜3.５モル、バリンを1.５〜2.０モル、プロリン
を5.２〜5.６モル、およびアラニンを1.６〜2.０モルの
割合で含有することができる。The fatty acid mainly composed of isoleucine, leucine, valine, serine, proline, glycine, alanine and threonine and the sugar metabolism regulator of the present invention are preferably 1.2 to 1.5 moles of isoleucine and leucine. To 1.
6-2.1 mol, valine 1.5-2.0 mol, serine 0.5
~ 0.9 mol, proline 5.2-5.6 mol, glycine 5.
It may contain 5 to 6.0 moles, alanine in 1.6 to 2.0 moles, and threonine in a proportion of 2.0 to 2.4 moles. Further, isoleucine, leucine, lysine of the present invention,
The fatty acid mainly composed of valine, proline, glycine, and alanine, and the sugar metabolism regulator are preferably 1.2 to 1.6 mol of isoleucine, 1.6 to 2.2 mol of leucine, and 3. 0-3.5 mol, valine 1.5-2.0 mol, proline 5.2-5.6 mol, glycine 5.5-6.0 mol, and alanine 1.6-2.0. It can be contained in a molar ratio. Furthermore, the fatty acid mainly composed of isoleucine, leucine, lysine, valine, proline, and alanine of the present invention, the sugar metabolism regulator is preferably 1.2 to 1.5 moles of isoleucine and 1.6 to leucine. 2.1 mol, lysine 3.0-3.5 mol, valine 1.5-2.0 mol, proline 5.2-5.6 mol, and alanine 1.6-2.0 mol. It can be contained in a ratio.
【０００６】以下の表１は、本発明の好ましい態様を示
すものであるが、本発明はこの態様に限定されることは
ない。Although Table 1 below shows a preferred embodiment of the present invention, the present invention is not limited to this embodiment.
【０００７】[0007]
【表１】 表１：本発明の代謝調節剤のアミノ酸組成 本発明の代謝調節剤 (1) (2) (3) (4) ─────────────────────────────────── mg/dl(モル%) mg/dl(モル%) mg/dl(モル%) mg/dl(モル%) Ｉｌｅ 8 9.2(0.68) 1 7 8.4(1.36) 1 7 8.4(1.36) 1 7 8.4(1.36) ア Ｌｅｕ 1 2 1.2(0.92) 2 4 2.4(1.85) 2 4 2.4(1.85) 2 4 2.4(1.85) Ｌｙｓ 2 3 6.9(1.62) 0 4 7 3.8(3.24) 4 7 3.8(3.24) ミ Ｖａｌ 1 0 3.2(0.88) 2 0 6.4(1.76) 2 0 6.4(1.76) 2 0 6.4(1.76) Ｓｅｒ 3 9.2(0.37) 7 8.4(0.74) 0 0 ノ Ｐｒｏ 3 1 2.0(2.71) 6 2 4.0(5.42) 6 2 4.0(5.42) 6 2 4.0(5.42) Ｇｌｙ 2 1 5.6(2.87) 4 3 1.2(5.74) 4 3 1.2(5.74) 0 酸 Ａｌａ 8 2.0(0.92) 1 6 4.0(1.84) 1 6 4.0(1.84) 1 6 4.0(1.84) Ｔｈｒ 1 2 8.0(1.07) 2 5 7.0(2.15) 0 0 ─────────────────────────────────── 本発明の代謝調節剤の製造にあたっては、市販の上記ア
ミノ酸を上記の所定割合で混合すれば良い。本発明代謝
調節剤は、特にＬ−アミノ酸を用いることが好ましい。
通常は粉末状で均一に混合して代謝調節剤とすればよい
が、構成成分を蒸留水に溶解し若しくは溶液状態で混合
し、乾燥して本発明の代謝調節剤を製造してもよい。本
発明の代謝調節剤を製造するにあたって温度は特に限定
されないが、室温以下で製造することが好ましい。本発
明の代謝調節剤はマウスに経口投与した場合２０ｇ／kg
でも全く毒性を発現せず、ＬＤ50は２０ｇ／kgをはるか
に上まわる。Table 1: Table 1: Amino acid composition of the metabolic regulator of the present invention Metabolic regulator of the present invention (1) (2) (3) (4) ───────────────── ─────────────────── mg / dl (mol%) mg / dl (mol%) mg / dl (mol%) mg / dl (mol%) Ile 8 9.2 (0.68) 1 7 8.4 (1.36) 1 7 8.4 (1.36) 1 7 8.4 (1.36) A Leu 1 2 1.2 (0.92) 2 4 2.4 (1.85) 2 4 2.4 (1.85) 2 4 2.4 (1.85) Lys 2 3 6.9 (1.62) 0 4 7 3.8 (3.24) 4 7 3.8 (3.24) Mi Val 1 0 3.2 (0.88) 2 0 6.4 (1.76) 2 0 6.4 (1.76) 2 0 6.4 (1.76) Ser 3 9.2 (0.37) 7 8.4 (0.74) 0 0 No Pro 3 1 2.0 (2.71) 6 2 4.0 (5.42) 6 2 4.0 (5.42) 6 2 4.0 (5.42) Gly 2 1 5.6 (2.87) 4 3 1.2 (5.74) 4 3 1.2 (5.74 ) 0 Acid Ala 8 2.0 (0.92) 1 6 4.0 (1.84) 1 6 4.0 (1.84) 1 6 4.0 (1.84) Thr 1 2 8.0 (1.07) 2 5 7.0 (2.15) 0 0 ───────── ─────────────────────────── In the production of the metabolic regulator of the present invention, commercially available amino The may be mixed at a predetermined ratio described above. It is particularly preferable to use L-amino acids as the metabolic regulator of the present invention.
Usually, it may be powdered and uniformly mixed to obtain a metabolic regulator, but the constituents may be dissolved in distilled water or mixed in a solution state and dried to produce the metabolic regulator of the present invention. The temperature for producing the metabolic regulator of the present invention is not particularly limited, but it is preferably produced at room temperature or lower. The metabolic regulator of the present invention is 20 g / kg when orally administered to mice.
However, it showed no toxicity at all, and the LD 50 far exceeded 20 g / kg.
【０００８】本発明の代謝調節剤は微弱な苦味を呈し、
運動時に乳酸の生成を抑制する。また、血中乳酸値を低
下することにより疲労の低下や運動持続に有用である。
本発明の代謝調節剤は、安静時および運動時の疲労回
復、ならびに筋運動持続に有用である。また神経作用剤
としても有用である。投与形態は特に限定されないが、
経口投与、直腸投与、注射、輸液による投与等の一般的
投与経路により投与することができる。経口投与の場合
には、上記代謝調節剤自体を投与してもよいが、医薬上
許容される担体、賦形剤、希釈剤等とともに混合し、散
剤、顆粒剤、錠剤、カプセル剤、トローチ剤、シロップ
剤等の製剤を製造して投与してもよい。ただし、固体散
剤、錠剤では吸収に時間がかかる場合もあるので、上記
の代謝調節剤自体を経口投与することが好ましい。その
場合には、適当な添加剤、例えば塩化ナトリウム等の塩
類、pH調節剤、キレート剤等と共に水溶液として投与す
ることが好ましい。The metabolic regulator of the present invention exhibits a weak bitterness,
Inhibits the production of lactic acid during exercise. In addition, lowering blood lactate level is useful for reducing fatigue and maintaining exercise.
INDUSTRIAL APPLICABILITY The metabolic regulator of the present invention is useful for recovering from fatigue during rest and exercise, and for maintaining muscle movement. It is also useful as a nerve agent. The dosage form is not particularly limited,
It can be administered by a general administration route such as oral administration, rectal administration, injection and administration by infusion. In the case of oral administration, the above-mentioned metabolic regulator itself may be administered, but it is mixed with a pharmaceutically acceptable carrier, excipient, diluent, etc., and then powder, granules, tablets, capsules, troches. Alternatively, a preparation such as a syrup may be manufactured and administered. However, solid powders and tablets may take a long time to be absorbed, so it is preferable to orally administer the above-mentioned metabolic regulator itself. In that case, it is preferable to administer it as an aqueous solution together with appropriate additives, for example, salts such as sodium chloride, pH adjusters, chelating agents and the like.
【０００９】本発明の代謝調節剤には、他のアミノ酸、
水溶性ビタミン類、クエン酸等の酸類を添加してもよ
く、また、適当な風味を加えてドリンク剤（たとえば清
涼飲料、粉末飲料、滋養強壮、栄養補給を目的とした医
薬品としての飲料）としてもよい。また、注射剤として
は、適当な緩衝剤、等張剤等を添加し、滅菌蒸留水に溶
解したものを用いればよい。The metabolic regulator of the present invention includes other amino acids,
Water-soluble vitamins, acids such as citric acid may be added, or as a drink with an appropriate flavor (for example, soft drinks, powdered drinks, nutritional tonics, drinks as pharmaceuticals for nutritional support) Good. As the injection, a suitable buffer, isotonicity agent, etc. may be added and dissolved in sterile distilled water.
【００１０】本発明の代謝調節剤はきわめて低毒性であ
るから、その投与量は非常に広範に設定することができ
る。投与量は投与方法、使用目的により異なるが、通常
１回に0.５〜５ｇ、好ましくは１回に１〜２ｇ、１日投
与量として１〜２０ｇ、好ましくは４〜１０ｇとするこ
とが好ましい。これらの溶液剤とする場合には、0.５〜
１０wt％溶液として１０〜１０００ml、好ましくは１〜
４wt％溶液として１００〜４００mlを１回投与量とすれ
ばよい。Since the metabolic regulator of the present invention has extremely low toxicity, its dose can be set within a very wide range. Although the dose varies depending on the administration method and purpose of use, it is usually 0.5 to 5 g at a time, preferably 1 to 2 g at a time, and a daily dose of 1 to 20 g, preferably 4 to 10 g . When using these solutions, 0.5-
10-1000 ml as a 10 wt% solution, preferably 1-
A single dose may be 100 to 400 ml as a 4 wt% solution.
【００１１】[0011]
【実施例】表１に記載された本発明の代謝調節剤、およ
びオオスズメバチの組成を有する組成物カゼインアミノ
酸組成物（ＣＡＡＭ、表２）を、室温下で蒸留水に対し
て成分アミノ酸を加えて溶解することにより、１６mg/m
l の水溶液(1.6wt％）を製造した。EXAMPLE A composition having the composition of the metabolic regulator of the present invention shown in Table 1 and a hornet vespid A casein amino acid composition (CAAM, Table 2) was prepared by adding component amino acids to distilled water at room temperature. 16mg / m by dissolving
An aqueous solution of l (1.6 wt%) was prepared.
【００１２】[0012]
【表２】 ───────────────────────────────── アミノ酸 ＣＡＡＭ モル％ (mg/dl) ───────────────────────────────── Ｈｉｓ ５3.０ 2.３ Ａｒｇ ６7.０ 2.６ Ｉｌｅ ９4.８ 4.９ Ｌｅｕ １７0.２ 8.９ Ｌｙｓ １４5.２ 6.８ Ｍｅｔ ５0.２ 2.３ Ｃｙｓ 8.２ 0.２ Ｐｈｅ ９2.２ 3.８ Ｔｙｒ １０3.４ 3.９ Ｔｈｒ ８3.８ 4.８ Ｔｒｐ ２8.0 0.９ Ｖａｌ １２0.０ 7.０ Ａｓｐ １２5.６ 6.５ Ｓｅｒ １０9.０ 7.１ Ｇｌｕ ３９0.８ １8.２ Ｐｒｏ ２０6.６ １2.３ Ｇｌｙ ３6.４ 3.３ Ａｌａ ５3.２ 4.１ ───────────────────────────────── 試験例 強制遊泳試験を行った。試験方法としては、５週令（１
９〜２０ｇ）のddy 系雄マウスを１群１０匹とし、検体
として、上記の水溶液、または２０％グルコースを３7.
５μl 投与し、投与３０分後にマウスを直径３２cm、深
さ３０cmの水槽に４〜８ｍ／分の流速を作って６０分間
にわたり強制負荷遊泳（0.３ｇの負荷）させ、血中の遊
離脂肪酸、血中のグルコースを測定した。 (1) 血中遊離脂肪酸の定量：遊泳終了後、直ちにエーテ
ルにより麻酔を施して開腹し、腹部大静脈から採血を行
った。採血した血液を遠心分離して血球成分を除き、遠
心分離後の上清について、和光純薬工業社製の臨床試薬
を用いて、常法に基づき脂肪酸定量を行った。脂肪酸の
定量は、特願平２−２４０９６１号に記載された方法に
準じ、アシル− CoA合成酵素とアシル−CoA オキシダー
ゼの作用により生じた過酸化水素をペルオキシダーゼと
反応させ、エチル−Ｎ−アニリンと４−アミノアンピリ
ンを呈色させたものを５５０nmで吸光度を測定した。 (2) 血中グルコーステスト：ヘキソキナーゼとグルコー
ス−６−リン酸デヒドロゲナーゼによってグルコースが
６−リン酸δグルコノラクトンに変わる時に１分子生成
するNADPH を３４０nmの吸収測定によって求めた。ベー
リンガー社の臨床試薬を用いた。[Table 2] ───────────────────────────────── Amino acid CAAM mol% (mg / dl) ──── ───────────────────────────── His 53.0 2.3 Arg 67.0 2.6 Ile 94.8 4.9 Leu 170.2 8.9 Lys 145.2 6.8 Met 50.2 2.3 Cys 8.2 0.2 0.2 Phe 92.2 3.8 Tyr 103.4 3.9 Thr 83.8 4.8 Trp 28.0 0.9 Val 120.0 7.0 Asp 125.6 6.5 Ser 109.0 7.1 Glu 390.8 18.2 Pro 206.6 12.3 Gly 36.4 3.3 Ala 53 .2 4.1 ───────────────────────────────── Test example A forced swimming test was conducted. The test method is 5 weeks old (1
9 to 20 g) ddy male mice were used as one group, and the above-mentioned aqueous solution or 20% glucose was used as a specimen.
5 μl was administered, and 30 minutes after administration, the mice were subjected to forced load swimming (load of 0.3 g) in a water tank having a diameter of 32 cm and a depth of 30 cm at a flow rate of 4 to 8 m / min for 60 minutes to obtain free fatty acid in blood, Blood glucose was measured. (1) Quantification of free fatty acids in blood: Immediately after swimming, anesthesia was anesthetized with ether to open the abdomen, and blood was collected from the abdominal vena cava. The collected blood was centrifuged to remove blood cell components, and the supernatant after centrifugation was quantified for fatty acids by a conventional method using a clinical reagent manufactured by Wako Pure Chemical Industries, Ltd. The quantification of fatty acids was carried out according to the method described in Japanese Patent Application No. 2-240961, by reacting hydrogen peroxide generated by the action of acyl-CoA synthase and acyl-CoA oxidase with peroxidase to obtain ethyl-N-aniline. The color of 4-aminoampyline was measured for absorbance at 550 nm. (2) Blood glucose test: NADPH, which forms one molecule when glucose is converted into 6-phosphate δ-gluconolactone by hexokinase and glucose-6-phosphate dehydrogenase, was determined by absorption measurement at 340 nm. The clinical reagent of Boehringer was used.
【００１３】[0013]
【表３】 測 定 値 NEFA(mEq/dl) 血糖(mg/dl) ─────────────────────────────────── 本発明の代謝調節剤 (1) 1.87±0.14 − (2) 1.75±0.11 80.58±2.28 (3) 1.73±0.12 85.88±1.04 (4) 2.34±0.47 54.15±12.21 ＣＡＡＭ 1.34±0.90 42.20±8.56 ────────────────────────────────── いずれも ｎ＝１０ 本発明の代謝調節剤(1) 、(2) 、(3) 、(4) のいずれの
組成でも強制運動後の、血中遊離脂肪酸はＣＡＡＭより
高い値を示し、脂肪酸の遊離を促進すること、また血糖
値はＣＡＡＭ投与群に比べて、高いことがわかった（表
３）。[Table 3] Measured values NEFA (mEq / dl) Blood glucose (mg / dl) ──────────────────────────────── ──── Metabolic regulator of the present invention (1) 1.87 ± 0.14 − (2) 1.75 ± 0.11 80.58 ± 2.28 (3) 1.73 ± 0.12 85.88 ± 1.04 (4) 2.34 ± 0.47 54.15 ± 12.21 CAAM 1.34 ± 0.90 42.20 ± 8.56 ────────────────────────────────── Both are n = 10 The metabolic regulator (1) of the present invention, (2), (3), and (4), free fatty acid in the blood after forced exercise shows a higher value than CAAM after forced exercise and promotes the release of fatty acid, and the blood glucose level is higher than that in the CAAM administration group. It was found to be high (Table 3).
【００１４】[0014]
【発明の効果】本発明の代謝調節剤は運動時に、脂肪酸
の遊離を促進し、血糖値を維持させるうえ、極めて低毒
性であり、脂肪酸、糖、乳酸代謝調節剤として有用であ
る。INDUSTRIAL APPLICABILITY The metabolic regulator of the present invention promotes the release of fatty acids during exercise and maintains the blood glucose level, and has extremely low toxicity, and is useful as a fatty acid, sugar and lactic acid metabolism regulator.
フロントページの続き (72)発明者 飯田 耕司 東京都中央区八丁堀３−28−14Front page continuation (72) Inventor Koji Iida 3-28-14 Hatchobori, Chuo-ku, Tokyo
Claims (8)
ン、セリン、プロリン、グリシン、アラニン、及びスレ
オニンを主成分として含む脂肪酸代謝調節剤。1. A fatty acid metabolism regulator containing isoleucine, leucine, lysine, valine, serine, proline, glycine, alanine, and threonine as main components.
ン、セリン、プロリン、グリシン、アラニン、及びスレ
オニンを主成分として含む糖代謝調節剤。2. A sugar metabolism regulator containing isoleucine, leucine, lysine, valine, serine, proline, glycine, alanine, and threonine as main components.
ン、プロリン、グリシン、アラニン、及びスレオニンを
主成分として含む脂肪酸代謝調節剤。3. A fatty acid metabolism regulator containing isoleucine, leucine, valine, serine, proline, glycine, alanine, and threonine as main components.
ン、プロリン、グリシン、アラニン、及びスレオニンを
主成分として含む糖代謝調節剤。4. A sugar metabolism regulator containing isoleucine, leucine, valine, serine, proline, glycine, alanine, and threonine as main components.
ン、プロリン、グリシン、及びアラニンを主成分として
含む脂肪酸代謝調節剤。5. A fatty acid metabolism regulator containing isoleucine, leucine, lysine, valine, proline, glycine, and alanine as main components.
ン、プロリン、グリシン、及びアラニンを主成分として
含む糖代謝調節剤。6. A sugar metabolism regulator containing isoleucine, leucine, lysine, valine, proline, glycine, and alanine as main components.
ン、プロリン、及びアラニンを主成分として含む脂肪酸
代謝調節剤。7. A fatty acid metabolism regulator containing isoleucine, leucine, lysine, valine, proline, and alanine as main components.
ン、プロリン、及びアラニンを主成分として含む糖代謝
調節剤。8. A sugar metabolism regulator containing isoleucine, leucine, lysine, valine, proline, and alanine as main components.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12725793A JP3553992B2 (en) | 1993-05-28 | 1993-05-28 | Metabolic regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12725793A JP3553992B2 (en) | 1993-05-28 | 1993-05-28 | Metabolic regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06336426A true JPH06336426A (en) | 1994-12-06 |
| JP3553992B2 JP3553992B2 (en) | 2004-08-11 |
Family
ID=14955576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12725793A Expired - Fee Related JP3553992B2 (en) | 1993-05-28 | 1993-05-28 | Metabolic regulator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3553992B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0983726A1 (en) * | 1998-08-24 | 2000-03-08 | Riken | Amino acid-trehalose composition |
| WO2005027898A1 (en) * | 2003-09-19 | 2005-03-31 | Riken | Amino acid compositions |
| WO2008105368A1 (en) * | 2007-02-28 | 2008-09-04 | Meiji Dairies Corporation | Amino acid composition |
| WO2010055895A1 (en) | 2008-11-11 | 2010-05-20 | 日本電気株式会社 | Mobile terminal, page transmission method for a mobile terminal and program |
| EP2210601A4 (en) * | 2007-10-31 | 2011-02-09 | Meiji Dairies Corp | Anti-fatigue agent comprising amino acid composition |
| US8012924B2 (en) | 2003-05-30 | 2011-09-06 | Riken | Amino acid composition and supplementary liquid containing the same |
| JP2017536388A (en) * | 2014-12-04 | 2017-12-07 | プロフェスィオナル ディエテティクス ソシエタ ペル アチオニＰｒｏｆｅｓｓｉｏｎａｌ Ｄｉｅｔｅｔｉｃｓ Ｓ．Ｐ．Ａ． | Amino acid based composition for recovery of fibroelastin in dermal connective tissue |
-
1993
- 1993-05-28 JP JP12725793A patent/JP3553992B2/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0983726A1 (en) * | 1998-08-24 | 2000-03-08 | Riken | Amino acid-trehalose composition |
| US8012924B2 (en) | 2003-05-30 | 2011-09-06 | Riken | Amino acid composition and supplementary liquid containing the same |
| US8012926B2 (en) | 2003-05-30 | 2011-09-06 | Riken | Amino acid composition and supplementary liquid containing the same |
| WO2005027898A1 (en) * | 2003-09-19 | 2005-03-31 | Riken | Amino acid compositions |
| WO2008105368A1 (en) * | 2007-02-28 | 2008-09-04 | Meiji Dairies Corporation | Amino acid composition |
| AU2008220128B2 (en) * | 2007-02-28 | 2013-07-11 | Meiji Co., Ltd. | Amino acid composition |
| JP5812565B2 (en) * | 2007-02-28 | 2015-11-17 | 株式会社明治 | Amino acid composition |
| EP2210601A4 (en) * | 2007-10-31 | 2011-02-09 | Meiji Dairies Corp | Anti-fatigue agent comprising amino acid composition |
| WO2010055895A1 (en) | 2008-11-11 | 2010-05-20 | 日本電気株式会社 | Mobile terminal, page transmission method for a mobile terminal and program |
| JP2017536388A (en) * | 2014-12-04 | 2017-12-07 | プロフェスィオナル ディエテティクス ソシエタ ペル アチオニＰｒｏｆｅｓｓｉｏｎａｌ Ｄｉｅｔｅｔｉｃｓ Ｓ．Ｐ．Ａ． | Amino acid based composition for recovery of fibroelastin in dermal connective tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3553992B2 (en) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2873497B2 (en) | Lipid metabolism regulator | |
| EP1629840B1 (en) | Amino acid composition and fluid replacement | |
| EP0983726B1 (en) | Amino acid-trehalose composition | |
| US6221836B1 (en) | Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal | |
| JP2009242413A (en) | Medicine based on amino acid | |
| CA2261708A1 (en) | Composition of pyruvate and protein and method for increasing protein concentration in a mammal | |
| AU627041B2 (en) | Improved nutritional formulation for the treatment of renal disease | |
| EP1374863B1 (en) | Amino acid compositions for ameliorating liver failure | |
| JP2518692B2 (en) | Muscle maintenance agent, nutrient tonic, infusion agent, nutritional supplement, fatigue recovery agent and lactic acid production regulator | |
| US5424074A (en) | Pharmaceutical composition for potassium supplementation | |
| JPH06336426A (en) | Metabolic regulator | |
| WO2004032917A1 (en) | Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction | |
| JP2001518484A (en) | Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and for preventing abuse of alcohol in healthy people | |
| JP2873493B2 (en) | Blood sugar regulator | |
| US6506552B2 (en) | Amino acid-trehalose composition | |
| JP2002512191A (en) | A composition comprising L-carnitine or alkanoyl L-carnitine and NADH and / or HADPH. | |
| JP3096052B2 (en) | Lipid metabolism regulator | |
| US20080161380A1 (en) | Amino acid composition | |
| EP0363337A1 (en) | Energy substrate containing hydroxycarboxylic acid | |
| HU229214B1 (en) | Combination composition comprising propionyl l-carnitine and further drug for the treatment of erectile dysfunction | |
| JPH06336432A (en) | Adrenaline and noradrenaline secretion promoting composition | |
| JPS61134313A (en) | Agent for suppressing toxicity of aldehyde | |
| EP0429679A1 (en) | Potassium-supplementing preparation | |
| JPH06271465A (en) | Long acting ascorbic acid preparation | |
| JPH03127739A (en) | Alcohol absorption suppressant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20031027 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20031201 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040323 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040413 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20040413 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040426 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040506 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050506 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080514 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090514 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090514 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100514 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |